Expert insights from EADV 2019 and the evolution of 'psoriasis-targeted' treatments
At the EADV Congress 2019 we interviewed psoriasis key opinion leaders Professors Andrew Blauvelt and Ulrich Mrowietz about their experience and opinions. They discuss the challenges in treating psoriasis and some of the principles in selecting treatment. See the below video selections.
Our featured video asks Professor Andrew Blauvelt to discuss the importance of head-to-head studies in providing targeted psoriasis treatments. See below:
Scroll through the list of questions below to hear from Professors Blauvelt and Mroweitz.
Professor Blauvelt discusses physician and patient education that is important to challenge the initial perception that biologics had safety issues. Find out how the evolution of ‘psoriasis-targeted’ treatments dispels this myth.
Professor Blauvelt introduces clinical factors that dermatologists should consider when selecting a targeted treatment for mild to moderate psoriasis. In particular, he stresses the need to move beyond stratifications based on severity to patient-centric care.
The most appropriate targeted treatment may dependent partly on the patient’s age and their likelihood of good adherence, Professor Blauvelt says. According to Professor Blauvelt, psoriatic arthritis may be more common than many dermatologists realise and is important when individualising treatment.
Professor Blauvelt reviews why considering the speed of a targeted treatment’s onset of action and the likelihood that the response will be maintained long term helps dermatologists tailor treatment to each patient.
Modern treatments offer the opportunity to markedly improve outcomes in most psoriasis patients. However, Professor Mrowietz points out, dermatologists face several challenges when delivering optimal pharmacological care.
Professor Mrowietz discusses the growing recognition that psoriasis may be a systemic, rather than purely dermatological, disease. In particular, he points out, vascular inflammation can increase the risk of cardiovascular disease.
Professor Mrowietz argues that clinical studies now need to determine whether managing the dermatological manifestations of psoriasis also improves comorbidities. However, the benefits of older treatments may remain unexplored.
The introduction of biologics for psoriasis transformed treatment for many patients. Nevertheless, Professor Mrowietz suggests, non-biological systemic treatments still have an important role for selected psoriasis patients.
Professor Andrew Blauvelt - Meet Andrew Blauvelt, Professor of Dermatology at Oregon Health & Science University and President of the Oregon Medical Research Center. Find out why his family history enables him to empathise with his patients. During the 2019 European Academy of Dermatology and Venereology (EADV) Congress, epgonline.org spoke to Professor Blauvelt about the benefits of targeted treatments in mild to moderate psoriasis, the factors that dermatologists should consider when agreeing a treatment with patients and the ideal approach to switching treatment. Professor Blauvelt partly bases his patient-centric approach on his family’s experiences of living with psoriasis.
Professor Ulrich Mrowietz - Meet Professor Ulrich Mrowietz, Head of the Psoriasis Centre at the University Medical Centre Schleswig-Holstein, Kiel Campus. Find out his experience in treating psoriasis and why he finds the diverse field of dermatology so interesting to work in. During the 2019 European Academy of Dermatology and Venereology (EADV) Congress, epgonline.org spoke to Professor Mrowietz about unmet needs in psoriasis care, the increasing recognition that psoriasis is a systemic disease and the evolution of pharmacological management. Professor Mrowietz also discussed the importance of considering clinically relevant outcomes and including comorbidities in clinical studies.